Monday, September 16, 2019

BP1 - Microglial alterations and depressive symptoms


I though this was a very well written article, describing a thorough and calculated experimental procedure and its results. The introduction clearly laid out the issues in developing new therapeutics for depression and how this is potentially related to the under-study of microglia, despite signs of microglial abnormality in depressive patients and other neurological disease. This laid out a good framework for why the study was conducted and what it hoped to achieve.
Within the materials and methods section, I was slightly confused as to why the behavioral tests were performed during the dark phase in the light dark cycle. Would removing the animals from the dark room and moving them to a bright testing room not influence their circadian rhythms in way that could act as a confounding variable? I am also curious as to if there was any variability in results between the different CUS paradigms. Tilting the cage seems to be significantly less extreme than exposing the rats to a strobe light or water deprivation. The accuracy of the behavioral measurements in assessing degree of depressive symptoms in rodents would also interest me. I know that it is hard to diagnose a mouse with depression, but it seems like many other factors could be influencing changes in social exploration or the open field test for example. The pharmacological interventions used were initially confusing but made more sense once they were discussed in the results section and the purpose of each administration was discussed in more detail.
The localization of decreased microglia was interesting, it does make sense that there would be no significant difference in the somatosensory cortex, as depression generally does not seem to influence sensory perception. Also, as there was a strong negative correlation between microglial expression and anhedonia it would be interesting to use this data to see if certain CUS paradigms are more effective than others. I was impressed at how the minocycline and imipramine were used to provide evidence that it is the initial microglial activation that leads to the eventual microglial apoptosis. This extra step really solidifies the results of the study.
Overall, I think that this article addressed two important and interesting issues within the field of Neuroscience: the oversimplification of glial cell function as well as the multifaceted and complicated etiology of depression. It provides strong evidence for stress induced increase in microglial activity leading to later microglial apoptosis, correlated with depressive behavior. In addition to this the article introduces GM-CSF as a treatment which increased microglial proliferation and reversed depressive symptoms in terms of sucrose preference. Given these results, I was surprised that the article was published in 2014 but this was the first time I heard anything about the issues discussed. While I don’t actively read scientific literature about the neuroscience of depression, I would have expected the information from the article to come up in some of the psychology or BNS classes I have taken. It seems that depression is discussed to some extent in every psych and neuro class I have taken but usually just in relationship to serotonin. I am also aware that it takes extremely long for clinical therapeutics to be developed from animal studies, but I am interested if there are any projects in the works.

1 comment:

  1. Agreed about testing during the dark cycle--often investigators want to assess behavior during the rodent's active phase (dark), but moving them through the hallways, etc could be problematic. My guess is the behavior rooms themselves were also dark/lit with red light. Glad this introduced you on to the immune signaling story of depression!

    ReplyDelete

Note: Only a member of this blog may post a comment.